Normal and pathological immune responses function across tissues that harbor unique metabolic, environmental, and cellular microenvironments. Therefore the mechanisms that recruit and activate leukocytes, define their interstitial function and survival, or promote their retention in particular tissues are crucial to understanding how to boost, redirect, or restrict immune responses across the spectrum of health and disease. While the topic of tissue specific immunity has been touched on in other meetings, this is the first conference to integrate discussion across diverse tissues and disease contexts. The program will cover how various tissues shape the immune responses that are generated within, while highlighting emerging technologies that are enabling advancements in this field.

Tailored to early-to-mid career scientists and clinicians in the field of cancer immunotherapy working in academic, clinical, industry and government settings, this hybrid program provides the best in cancer immunotherapy education taught by leading experts in the field.

Winter School participants gain a deep understanding of the core principles of tumor immunology and cancer immunotherapy, and developing areas in the field including biomarker technology, validation and clinical integration, clinical trial design, data analysis and considerations for combination therapies.

The Society for Immunotherapy of Cancer (SITC) Clinical Immuno-Oncology Network (SCION) Workshop is an intimate immunotherapy clinical trial development program, led by experts in the field who are equipped to help their assigned students navigate through the unique considerations that accompany immunotherapy treatments.

This new major conference will encompass the very best of basic, translational, and clinical research in immunology, inflammation and immunotherapies for cancer, including immuno-oncology (IO) drugs, inflammatory modulators, vaccines, and cellular therapies. The cutting-edge AACR IO 2025 program will appeal to a wide audience of basic scientists, translational researchers, clinical investigators, regulators, industry, investors, and lay press. A mix of keynote lectures, major symposia, spotlight sessions, educational sessions, special sessions, and poster sessions with exhibits will cover the spectrum of the IO field – including late-breaking clinical trials sessions highlighting new agents and IO combinations, and the results of practice-changing clinical trials.

The SITC Spring Scientific, Cellular Therapy for Solid Tumors, will address the recent advances in adoptive cellular therapy for solid tumors and rate-limiting challenges that impede bringing these novel therapies to patients in need. The program will feature in-depth discussions of the latest scientific insights and advances in the field and unique opportunities and unanswered questions in the areas of target antigen selection, product design, and therapeutic efficacy and safety.

Scientific Organizers: Christian U Blank, Stefani Spranger and Anna Christina Obenauf

Important Meeting Deadlines: Early Registration Deadline: Jan. 28, 2025; Scholarship Deadline: Dec. 9, 2024; Short Talk Abstract Deadline: Dec. 9, 2024; Poster Abstract Deadline: Feb. 20, 2025

Hear directly from science and business stakeholders on the latest data impacting IO to fight a wider range of cancers.

The Summit for Cancer Immunotherapy (Summit4CI) is the annual scientific meeting of BioCanRx - Canada’s Immunotherapy Network. Summit4CI brings together up to 350 leading scientists, clinicians, students and economists with representatives from industry, patient groups, charities and government. The conference explores the latest progress in cancer immunotherapy from scientific, clinical, industry and patient perspectives, through internationally recognized speakers, scientific presentations, poster sessions, panel discussions an Oxford-style debate and networking opportunities.

The AACR Annual Meeting is the critical driver of progress against cancer, the place where scientists, clinicians, other health care professionals, survivors, patients, and advocates gather to share and discuss the latest breakthroughs. From population science and prevention; to cancer biology, translational, and clinical studies; to survivorship and advocacy; the AACR Annual Meeting showcases cutting-edge cancer science and medicine.

Every year, the CIMT Annual Meeting connects the global cancer immunotherapy community in the heart of Europe. As the largest meeting focused on cancer immunotherapy research and development in Europe, CIMT invites international participants for high-level scientific exchange, collaboration, and education focused on cancer immunotherapy.

The target audience for this conference is basic and translational scientists and clinicians, both senior and young investigators that want to have a broad overview and detailed knowledge of the most recent advances in the field of immunotherapy.

Topics to be covered: Immune checkpoints; Innate immune response; Microbioma; Immune cell therapies; Vaccines; Biomarkers of response to immunotherapy; Mechanisms of resistance to immunotherapy

TBD

ESMO 2025 will be a place where groundbreaking discoveries, cutting-edge treatments and a collaborative approach converge to shape the future of cancer care.

You will be able to learn from internationally renowned experts, engage in thought-provoking discussions and connect with fellow oncology professionals that are driving advancements in diagnosis, treatment and survivorship.

Save the date for ESMO 2025, taking place in Berlin, Germany 17-21 October 2025.

Wednesday, Nov. 5–Sunday, Nov. 9, 2025, at the Gaylord National Resort and Convention Center National Harbor, Md. Details TBD.

This international event provides valuable knowledge: from basic science to translational research and clinical development, cutting-edge science, and excellent networking opportunities. Program TBD.

This meeting will bring together a diverse group of basic, translational and clinical researchers including those from academia, industry and government to cooperatively discuss the mechanistic basis of failed immunotherapy, and novel approaches to activating the immune system, in order to provide insight for future clinical applications of novel approaches and optimal combination therapies.